| Objective: To investigate the clinical efficacy of virtual reality technology combined with repetitive transcranial magnetic stimulation (rTMS) in the treatment of mild cognitive impairment in patients with Parkinson’s disease. Methods: A total of 64 patients with Parkinson’s disease were randomly divided into the control group and the observation group, 32 patients in each group. The control group was treated with conventional cognitive training and repetitive transcranial magnetic stimulation. The observation group was treated with virtual reality technology combined with rTMS. Before and 8 weeks after treatment, Montreal Cognitive Assessment (MoCA), Mini Mental State Examination (MMSE), the third subscale of the Unified Parkinson’s Disease Rating Scale (UPDRS Ⅲ) and the modified Barthel Index (MBI) were used to evaluate the cognitive function and activities of daily living of patients, and the total score of Parkinson’s Disease Quality of Life Questionnaire (PDQ-39) was used to evaluate the clinical efficacy. Results: After 8 weeks of treatment, the MMSE scores in the two groups were significantly improved as compared with those before treatment (P<0.01). Only the memory in the observation group was better than that in the control group after treatment (P<0.05), and there was no statistically significant difference in the comparison of the remaining sub-items and the total scores. The scores of visual space and executive function, memory and MoCA in the observation group were significantly higher than those before treatment (P<0.01), and the scores of attention were higher than those before treatment (P<0.05). The scores of visual space and executive function, memory and MoCA in the observation group after treatment were significantly higher than those in the control group (P<0.01), and the scores of attention were better than those in the control group after treatment (P<0.05). MBI scores in both groups were significantly higher than those before treatment (P<0.01), and MBI scores in the observation group were significantly higher than those in the control group (P<0.01). The total effective rate of the observation group was higher than that of the control group (P<0.05). Conclusion: Virtual reality technology combined with rTMS improve the cognitive and motor functions and activities of daily living of Parkinson’s patients, and improve their quality of life. |
